Combining gestrinone and Mifeprex (mifepristone) led to improved outcomes for endometriosis patients when compared to gestrinone alone, according to a new study. The therapeutic benefits included decreased hormone levels and enhanced pregnancy outcomes.
The study, “Therapeutic effects of mifepristone combined with Gestrinone on patients with endometriosis,” was published in the Pakistan Journal of Medical Sciences.
A team of researchers investigated the effects of combining Mifeprex with gestrinone, two of the most frequently used drugs for endometriosis in China, and evaluated the effect in a clinical setting with endometriotic patients.
Gestrinone is approved in Europe, Latin America, and other regions, but has not been approved for use in the United States. Mifeprex, while FDA-approved, has not been approved to treat endometriosis in the U.S.
Chinese researchers selected 150 patients who were admitted to the Affiliated Hospital of Hebei University in China between January 2014 and December 2015. Patients were randomly divided into two groups – a control group treated with gestrinone capsules alone and the treatment group treated with Mifeprex tablets and gestrinone capsules.
Specifically, the control group received oral gestrinone twice a week the second day after menstruation started. The treatment group received the same dose of gestrinone, in addition to Mifeprex tablets, administered once a day. The treatment was for 24 weeks.
After this period, researchers evaluated the clinical therapeutic effects in the two groups. Parameters evaluated included pelvic symptom score, clinical sign score, serum sex hormone levels and pregnancy outcomes.
Researchers found that the scores of pelvic symptoms, such as dysmenorrhea (menstrual cramps), dyspareunia (pain during sexual intercourse), and pelvic pain, and clinical signs (pelvic tenderness, induration) were significantly reduced in both groups. However, the decrease was always more significant in the combination treatment group (Mifeprex and gestrinone) compared to the control group (gestrinone capsules alone).
Additionally, the levels of several hormones (serum follicle hormone, luteinizing hormone, estrogen and progesterone) were significantly lower than those before treatment, and the reduction was once again more significant in the combo treatment group. The pregnancy rates in the six and 12 months of follow-up were 28% and 13.3% in the control group, and 42.7% and 29.3% in the treatment group, respectively.
Overall, these results show that combining gestrinone with Mifeprex can not only significantly alleviate clinical symptoms of endometriosis by reducing sex hormone levels, but also improves patients’ pregnancy outcomes.